Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605479178 | ||
| 003 | CHVBK | ||
| 005 | 20210128100409.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150301xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10741-014-9453-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10741-014-9453-8 | ||
| 245 | 0 | 0 | |a Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis |h [Elektronische Daten] |c [Chirag Bavishi, Saurav Chatterjee, Sameer Ather, Dipen Patel, Franz Messerli] |
| 520 | 3 | |a Beta-blockers are established drugs in heart failure with reduced ejection fraction, but their role in heart failure with preserved ejection fraction (HFpEF) is not established. Hence, we undertook a meta-analysis to evaluate the efficacy of beta-blockers on mortality and morbidity in HFpEF patients. A systematic search using PubMed, Embase, Scopus and Cochrane databases was performed to identify all relevant studies on beta-blockers and HFpEF. A random-effects model was performed to assess the role of beta-blockers on all-cause mortality and HF hospitalization. Overall 15 observational studies and two randomized control trial involving a total of 27,099 patients were included in the analysis. In the observational studies, beta-blocker therapy was associated with lower all-cause mortality [RR 0.81 (0.72-0.90), p<0.001], but not HF hospitalization [RR 0.79 (0.57-1.10), p<0.001]. However, in the two RCTs, the use of beta-blocker was not associated with all-cause mortality [RR 0.94 (0.67-1.32), p=0.72] or HF hospitalization [0.90 (0.54-1.49), p=0.68]. The results were consistent by geographic region (USA vs. rest of world) and ejection fraction subgroups. Subgroup analysis revealed that the beneficial survival effect of beta-blocker was limited to studies with mean age <75years. Observational studies showed a significant benefit from the use of beta-blockers for all-cause mortality, but not for HF hospitalization. Beta-blockers in the two RCTs were not associated with significant reduction in all-cause mortality or HF hospitalization; however, both the trials were not adequately powered and had high loss to follow-up rates. Further large sampled well-conducted randomized trials are warranted to confirm the effects of beta-blockers on mortality and hospitalization. | |
| 540 | |a Springer Science+Business Media New York, 2014 | ||
| 690 | 7 | |a Beta-blockers |2 nationallicence | |
| 690 | 7 | |a Heart failure with preserved ejection fraction |2 nationallicence | |
| 690 | 7 | |a Meta-analysis |2 nationallicence | |
| 700 | 1 | |a Bavishi |D Chirag |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | |
| 700 | 1 | |a Chatterjee |D Saurav |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | |
| 700 | 1 | |a Ather |D Sameer |u Division of Cardiovascular diseases, University of Alabama at Birmingham, Birmingham, AL, USA |4 aut | |
| 700 | 1 | |a Patel |D Dipen |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | |
| 700 | 1 | |a Messerli |D Franz |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | |
| 773 | 0 | |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/2(2015-03-01), 193-201 |x 1382-4147 |q 20:2<193 |1 2015 |2 20 |o 10741 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10741-014-9453-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10741-014-9453-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bavishi |D Chirag |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Chatterjee |D Saurav |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ather |D Sameer |u Division of Cardiovascular diseases, University of Alabama at Birmingham, Birmingham, AL, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Patel |D Dipen |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Messerli |D Franz |u Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, 1000 Tenth Ave, 10019, New York, NY, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/2(2015-03-01), 193-201 |x 1382-4147 |q 20:2<193 |1 2015 |2 20 |o 10741 | ||